Edgar Filing: NovaBay Pharmaceuticals, Inc. - Form 4

NovaBay Pharmaceuticals, Inc. Form 4 November 15, 2010

November	15, 2010								
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION								OMB APPROVAL	
	••••• UNITED					COMMISSION	OMB Number:	3235-0287	
Check t if no lor subject Section Form 4 Form 5 obligati may cor <i>See</i> Inst 1(b).	nger to 16. or Filed pur ons ntinue.	 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 						January 31, 2005 average urs per . 0.5	
(Print or Type	Responses)								
1. Name and Address of Reporting Person <u>*</u> WU ROY J			2. Issuer Name and Ticker or Trading Symbol NovaBay Pharmaceuticals, Inc. [NBY]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
		(Mon 11/1 C., 5980	tte of Earliest Tra hth/Day/Year) 2/2010	ansaction		Director X Officer (giv below) SVP Bus			
	(Street)		4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person 			
EMERYV	ILLE, CA 94608						More than One R		
(City)	(State)	(Zip)	Table I - Non-D	erivative	Securities A	.cquired, Disposed (of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)		3. if Transaction Code	4. Securiti Acquired Disposed (Instr. 3, 4	es (A) or of (D)	5. Amount of Securities Beneficially Owned	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect	
Reminder: Re	eport on a separate line	e for each class of	securities benefi	cially owr	ned directly of	or indirectly.			
				inform	ation cont	pond to the colle ained in this form and unless the for	are not	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

number.

displays a currently valid OMB control

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	f TransactiorDerivative Ex Code Securities (M		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount o Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Option (Right to buy) (1)	\$ 1.85	11/12/2010		A	40,000	11/12/2011(<u>2)</u>	11/12/2020	Common stock	40,000

Edgar Filing: NovaBay Pharmaceuticals, Inc. - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
WU ROY J C/O NOVABAY PHARMACEUTICALS, INC. 5980 HORTON STREET, SUITE 550 EMERYVILLE, CA 94608			SVP Bus & Corp Development			
Signatures						
/s/ Theresa Granados, as Attorney-in-Fact for Roy Wu		11/15/2010)			

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Granted pursuant to the NovaBay Pharmaceuticals, Inc. 2007 Omnibus Incentive Plan
- Twenty-five percent (25%) of the option shares vest and become exercisable upon the first anniversary of the date of grant and thereafter (2) the balance of the option shares vest and become exercisable in a series of twelve (12) equal installments upon the completion of each

Date

three (3) months beginning with November 12, 2011.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.